Coezy E, Darby I, Mizrahi J, Cantau B, Donnadieu M H, Nussberger J, Escher E, Chapnick B, Corvol P
Institut National de la Santé et de la Recherche Médicale, Unité 36 Paris, France.
Am J Physiol. 1989 Nov;257(5 Pt 1):C888-95. doi: 10.1152/ajpcell.1989.257.5.C888.
The aim of this study was to examine in Hep G2, a human hepatoma-derived cell line, the presence of angiotensin II (ANG II) receptors and the effect of ANG II and its analogues on angiotensinogen production. The presence of ANG II receptors was demonstrated using a long-acting ANG II analogue, 125I-labeled [Sar1]ANG II. A single class of specific binding sites was identified in these cells with a dissociation constant (Kd) of 2 nM. The number and affinity of these binding sites were not changed by [Sar1]ANG II treatment over 24 h. ANG II showed an inhibitory effect on angiotensinogen production. [Sar1]ANG II also exhibited a similar inhibitory effect as that of ANG II but to a greater extent and therefore was used throughout these studies. [Sar1]ANG II inhibited angiotensinogen production in a dose-dependent manner, exhibiting a half-maximal inhibitory concentration (IC50) of 2 nM. Other ANG II analogues showed similar effects on angiotensinogen production. In order of decreasing ability, they were [Sar1]ANG II greater than [Sar1-Ala8]ANG II greater than [Sar1-Val8]ANG II greater than [Sar1-Val5-(Br5)-Phe8]ANG II greater than [Sar1-Val5-DPhe8]ANG II. Results of these studies show that the Hep G2 cell possesses specific ANG II receptors and that [Sar1]ANG II induces a dose-dependent inhibition of angiotensinogen production in this system.
本研究的目的是在人肝癌衍生细胞系Hep G2中检测血管紧张素II(ANG II)受体的存在,以及ANG II及其类似物对血管紧张素原产生的影响。使用长效ANG II类似物125I标记的[Sar1]ANG II证明了ANG II受体的存在。在这些细胞中鉴定出一类特异性结合位点,其解离常数(Kd)为2 nM。这些结合位点的数量和亲和力在24小时内不受[Sar1]ANG II处理的影响。ANG II对血管紧张素原的产生具有抑制作用。[Sar1]ANG II也表现出与ANG II类似的抑制作用,但程度更大,因此在整个研究中都被使用。[Sar1]ANG II以剂量依赖的方式抑制血管紧张素原的产生,其半数最大抑制浓度(IC50)为2 nM。其他ANG II类似物对血管紧张素原的产生也表现出类似的作用。按作用能力递减顺序排列,它们依次为:[Sar1]ANG II>[Sar1-Ala8]ANG II>[Sar1-Val8]ANG II>[Sar1-Val5-(Br5)-Phe8]ANG II>[Sar1-Val5-DPhe8]ANG II。这些研究结果表明,Hep G2细胞具有特异性ANG II受体,并且[Sar1]ANG II在该系统中诱导血管紧张素原产生的剂量依赖性抑制。